VANDA PHARMACEUTICALS INC. Excess Tax Benefit from Share-based Compensation, Financing Activities
VANDA PHARMACEUTICALS INC. (VNDA) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $2.89 million for the 12-month period ending 2010-12-31, per its 10-K filed 2013-02-26.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2013-02-26
- VANDA PHARMACEUTICALS INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2010-12-31 was $1.23M.
- VANDA PHARMACEUTICALS INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2010-09-30 was $4.00K.
- VANDA PHARMACEUTICALS INC. excess tax benefit from share-based compensation, financing activities for fiscal 2010 was $2.89M.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2010-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $1.23M derived: sum of 2 quarters · filed 2013-02-26 | $2.89M 10-K · filed 2013-02-26 | |
| 2010-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | $1.66M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | $1.66M 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |